Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670155 | 0.90 | OPRL1 (0.39) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL2670173 | 0.89 | OPRL1 (0.39) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL15081928 | 0.86 | OPRL1 (0.37) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL2670070 | 0.84 | CYP3A4 (0.37) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL4748532 | 0.77 | HSD11B1 (0.39) | OPRL1METAP2KMT2AMAPK1CYP2D6 | |
| SCHEMBL2670581 | 0.75 | METAP2 (0.37) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL4795159 | 0.72 | CHRM2 (0.36) | OPRL1MAPTMAPK1CYP3A4CYP2D6 | |
| SCHEMBL4748562 | 0.71 | CYP2C19 (0.38) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL2670110 | 0.70 | MAPT (0.40) | OPRL1METAP2KMT2AMAPTMAPK1 | |
| SCHEMBL2670114 | 0.70 | MAPT (0.40) | OPRL1METAP2KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8618094-B2 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | OPRL1 782/4885METAP2 3650/4885KMT2A 2847/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | OPRL1 782/4885METAP2 3650/4885KMT2A 2847/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | OPRL1 782/4885METAP2 3650/4885KMT2A 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.